Quest rolls out new tests to assess breast cancer risk; Stanford scientists develop molecular imaging tech for bladder cancer detection;

> Quest Diagnostics ($DGX) is rolling out BRCAvantage Plus, the company's new suite of lab-developed tests for determining genetic breast cancer risk. Release

> Scientists at Stanford are developing an innovative molecular imaging technology that could improve bladder cancer detection and provide an alternative to standard endoscopy procedures. Release

> Researchers at the National Institutes of Health unveiled a new blood test that measures brain insulin resistance as an indicator of early-onset Alzheimer's disease. Release

> Charles River Laboratories ($CRL) acquired Cleveland, OH-based ChanTest in an all-cash transaction. Release

> Cleveland Clinic researchers are planning to use IBM's ($IBM) Watson technology to help oncologists uncover more personalized treatment options for cancer patients. Release

> French diagnostic outfit Genclis presented promising first clinical data for its molecular diagnostic test for nonmetastatic, triple-negative breast cancer. Release

> Clinical diagnostic firm Bio-Rad Laboratories agreed to shell out $55 million to settle foreign bribery allegations. Story (sub. req.)

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.